← Back to Screener
Actuate Therapeutics, Inc. Common stock (ACTU)
Price$1.88
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-83.29%
Price vs S&P 500 (4W)-43.02%
VGM Score17.38
Market Capitalization$44.98M
All Metrics
Book Value / Share (Quarterly)$0.16
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.83
Price vs S&P 500 (YTD)-77.44%
EPS (TTM)$-0.99
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-0.99
EPS (Annual)$-1.06
ROI (Annual)-266.87%
Cash / Share (Quarterly)$0.34
ROA (Last FY)-158.36%
EBITD / Share (TTM)$-0.99
Cash Flow / Share (Annual)$-0.83
P/B Ratio11.89x
P/B Ratio (Quarterly)17.16x
Net Income / Employee (Annual)$-1,852,300
Net Interest Coverage (TTM)-10.42x
ROA (TTM)-180.87%
EPS Incl Extra (Annual)$-1.06
Current Ratio (Annual)2.39x
Quick Ratio (Quarterly)1.72x
3-Month Avg Trading Volume0.12M
52-Week Price Return-79.32%
Revenue / Employee (TTM)$0
52-Week High$9.35
EPS Excl Extra (Annual)$-1.06
26-Week Price Return-75.36%
Quick Ratio (Annual)2.31x
13-Week Price Return-41.25%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)1.80x
Enterprise Value$37.25M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.57
3-Month Return Std Dev121.51%
Net Income / Employee (TTM)$-1,794,700
ROE (Last FY)-280.51%
EPS Basic Excl Extra (Annual)$-1.06
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-0.99
ROI (TTM)-195.99%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-103.68%
Year-to-Date Return-69.28%
5-Day Price Return-5.53%
EPS Normalized (Annual)$-1.06
Month-to-Date Return-6.93%
EBITD / Share (Annual)$-1.07
LT Debt / Equity (Annual)0.05x
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-0.99
P/B Ratio (Annual)17.95x
Book Value / Share (Annual)$0.34
Price vs S&P 500 (13W)-49.50%
Beta1.80x
Revenue / Share (TTM)$0.00
ROE (TTM)-206.50%
52-Week Low$1.58
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.24est. -0.22
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACTUActuate Therapeutics, Inc. Common stock | — | — | F | $1.88 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies targeting GSK-3, a key regulator of tumor cell survival and growth. The company's lead candidate, elraglusib, is designed to inhibit GSK-3B and disrupt oncogenic signaling pathways in difficult-to-treat cancers. Actuate is pursuing a novel mechanism of action to address cancers with limited therapeutic options.